Not logged in...
About USC Norris
Research
Patient Care
CISO
Search Trials
FAQ - Trials
Contact Us - Trials
Membership
Education
Shared Resources
Support USC Norris
Outreach
Login/Logout
Contact USC Norris
Support Us
Donate
Menu
USC Norris
»
Clinical Trials
Trial 3L-17-5
A multicenter, non-randomized, open-label dose escalation Phase Ib study of regorafenib in combination with pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) with no prior systemic therapy.
Type:
Treatment
Phase:
Phase I
Status:
Not Open (Closed)
Treatments:
Anti-Angiogenesis, Immunotherapy
Randomized:
No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:
Anthony El-Khoueiry, M.D.
Other Trial Staff:
Charlean Ketchens, Coordinator, Jiayi Jiang, D.M., Raluca Agafitei, Coordinator, Yanli Wang, D.M., Rabia Rehman, Coordinator
Staff may
log in
to see study documents.
Click here to see trial eligibility criteria and further details at ClinicalTrials.gov
For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or
clinical.trials@med.usc.edu
.
To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.